Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Drug Review Backlog Criticized At Appropriations Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

Sen. Kohl (D-Wisc.) requests a report on FDA’s efforts to improve its generic approval process.

You may also be interested in...

First Generic User Fees Proposed By Deputy Commissioner Gottlieb

GPhA says it would consider user fees for generics if FDA would endorse legislation to speed generics to the market.

Pediatric Exclusivity Would Be Reduced To Three Months Under Bipartisan Bill

The Lower PRICED Drugs Act from Sens. Lott (R-Miss.) and Stabenow (D-Mich.) also proposes to expand generic competition to non-“Orange Book”-listed antibiotics and to revise how 30-month stays are applied.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts